Literature DB >> 3155489

Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions.

B Adelman, A D Michelson, J Loscalzo, J Greenberg, R I Handin.   

Abstract

We have studied the effect of streptokinase on platelets in platelet-rich plasma (PRP) and of plasmin on washed platelets. By three and one-half minutes after the addition of 50,000 IU/mL streptokinase to PRP, the maximum rate of ristocetin-induced platelet agglutination declined 40%, and by 60 minutes, it declined 70%. During the same time interval, the thrombin time increased from 20 seconds to over 120 seconds. At a concentration as low as 50 IU/mL, streptokinase reduced the maximum rate of ristocetin-induced platelet agglutination by 50% and prolonged the thrombin time to 1.5 times control value. Streptokinase added to PRP also caused inhibition of platelet aggregation following stimulation by 2.9 mumol/L adenosine diphosphate, 0.25 U/mL thrombin, and 0.025 mg/mL collagen. Plasmin, 0.05 to 1.0 CU/mL, reduced ristocetin-mediated agglutination of washed platelets in the presence of von Willebrand factor (vWF) from 66% of control to 2% of control, following a one-hour incubation. Autoradiograms produced following sodium dodecyl-polyacrylamide gel electrophoresis (SDS-PAGE) of plasmin-treated 125I-surface-labeled platelets demonstrated progressive loss of a protein with a molecular weight (mol wt) of 180,000; simultaneously, a protein with mol wt 135,000 appeared on autoradiograms produced following SDS-PAGE of the surrounding platelet medium. These proteins are similar in molecular weight to glycoprotein (gp) Ib, a platelet surface receptor for vWF, and glycocalicin, a proteolytic fragment of gpIb. By use of an enzyme-linked immunosorbent assay (ELISA) based immunoinhibition assay for glycocalicin, we were able to demonstrate that plasmin treatment of washed platelets released a glycocalicin-related antigen into the surrounding medium and that appearance of this material corresponding to loss of vWF-dependent, ristocetin-induced agglutination.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3155489

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

Review 1.  A risk-benefit assessment of aprotinin in cardiac surgical procedures.

Authors:  W B Dobkowski; J M Murkin
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

2.  Plasminogen interacts with human platelets through two distinct mechanisms.

Authors:  L A Miles; M H Ginsberg; J G White; E F Plow
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

3.  von Willebrand protein facilitates platelet incorporation in polymerizing fibrin.

Authors:  J Loscalzo; A Inbal; R I Handin
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

4.  Platelet storage results in a redistribution of glycoprotein Ib molecules. Evidence for a large intraplatelet pool of glycoprotein Ib.

Authors:  A D Michelson; B Adelman; M R Barnard; E Carroll; R I Handin
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

Review 5.  Antifibrinolytic therapy in cardiac surgery.

Authors:  R H Chen; O H Frazier; D A Cooley
Journal:  Tex Heart Inst J       Date:  1995

6.  Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.

Authors:  C S Rinder; H M Rinder; B R Smith; J C Fitch; M J Smith; J B Tracey; L A Matis; S P Squinto; S A Rollins
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

7.  Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin.

Authors:  A I Schafer; A K Maas; J A Ware; P C Johnson; S E Rittenhouse; E W Salzman
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

8.  The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea.

Authors:  Shilpa Rahangdale; Susie Yim Yeh; Victor Novack; Karen Stevenson; Marc R Barnard; Mark I Furman; Andrew L Frelinger; Alan D Michelson; Atul Malhotra
Journal:  J Clin Sleep Med       Date:  2011-04-15       Impact factor: 4.062

Review 9.  Natural and synthetic antifibrinolytics in cardiac surgery.

Authors:  J F Hardy; J Desroches
Journal:  Can J Anaesth       Date:  1992-04       Impact factor: 5.063

Review 10.  Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris.

Authors:  J Loscalzo
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.